Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Common Equity (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Common Equity readings, the most recent being $87.3 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 22.64% to $87.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.3 million, a 22.64% decrease, with the full-year FY2025 number at $87.3 million, down 22.64% from a year prior.
  • Common Equity hit $87.3 million in Q4 2025 for Treace Medical Concepts, down from $89.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $157.6 million in Q1 2023 to a low of -$684000.0 in Q1 2021.
  • Median Common Equity over the past 5 years was $100.3 million (2021), compared with a mean of $99.7 million.
  • The widest YoY moves for Common Equity: up 130167.09% in 2021, down 137.92% in 2021.
  • Treace Medical Concepts' Common Equity stood at $93.1 million in 2021, then tumbled by 34.97% to $60.5 million in 2022, then skyrocketed by 127.89% to $137.9 million in 2023, then decreased by 18.16% to $112.9 million in 2024, then decreased by 22.64% to $87.3 million in 2025.
  • The last three reported values for Common Equity were $87.3 million (Q4 2025), $89.2 million (Q3 2025), and $97.6 million (Q2 2025) per Business Quant data.